MONTREAL, Feb. 7, 2024 /PRNewswire/ — Flexter.com, the innovative reservation platform for the short-term truck rental industry, is thrilled to announce a strategic partnership with Green Motion/ U-Save, a globally recognized provider of low CO2 car and van rentals. This collaboration will see Green Motion’s worldwide brand, including their prominent U-Save brand in the USA,… Continue reading Flexter.com and Green Motion Announce Strategic Partnership to Transform the Short-Term Truck Rental Reservation Process Worldwide
Category: Newswire
NEOM announces Xaynor, an exclusive private members club
NEOM, Saudi Arabia, Feb. 7, 2024 /PRNewswire/ — The Board of Directors of NEOM has announced Xaynor, a beachfront private members club, nestled among the rocky landscapes along the pristine coastline of the Gulf of Aqaba. Xaynor is the latest addition to the evolving regional development in northwest Saudi Arabia. Continue Reading NEOM announces Xaynor, an… Continue reading NEOM announces Xaynor, an exclusive private members club
Silicon Wafer Market to Reach $25.9 billion, Globally, by 2032 at 5.42% CAGR: Allied Market Research
The silicon wafer market is driven by factors such as rise in the demand for consumer electronics and semiconductors for the automotive industry. WILMINGTON, Del. , Feb. 8, 2024 /PRNewswire/ — Allied Market Research published a report, titled, “Silicon Wafer Market by Wafer Size (1 to 100mm, 100mm to 300mm, and above 300mm), Type (P type, N… Continue reading Silicon Wafer Market to Reach $25.9 billion, Globally, by 2032 at 5.42% CAGR: Allied Market Research
Orexa Announces First Patient Dosed in Phase 2 Trial in Post-Operative Patients
HERPEN, The Netherlands, Feb. 8, 2024 /PRNewswire/ — Orexa B.V., a Dutch life sciences company that is developing a new medicine that increases food intake and supports health in patients, announces that the first patient has been dosed in a Phase 2 clinical trial in the prevention of postoperative ileus. The trial investigates whether patients… Continue reading Orexa Announces First Patient Dosed in Phase 2 Trial in Post-Operative Patients
JELD-WEN Names Senior Leaders to Strengthen Customer Focus and Accelerate Business Performance
Gustavo Vianna joins as EVP and President, Europe Dan Valenti joins as EVP, North America Doors & Distribution Matt Meier joins as EVP, Chief Digital and Information Officer CHARLOTTE, N.C., Feb. 8, 2024 /PRNewswire/ — JELD-WEN Holding, Inc. (NYSE: JELD), a leading global manufacturer of building products, today announced three new leaders and a refreshed… Continue reading JELD-WEN Names Senior Leaders to Strengthen Customer Focus and Accelerate Business Performance
Tetra Pharm Technologies bringt den CB1-Antagonisten TPT0701 zur Appetitunterdrückung in die präklinische Testphase
Das dänische biopharmazeutische Unternehmen Tetra Pharm Technologies verkündet mit Stolz einen bedeutenden Meilenstein im Bereich der Appetitzügler-Forschung, indem es einen innovativen Wirkstoff entwickelt hat, der seine innovative Plattformtechnologie nutzt. KOPENHAGEN, Dänemark, 8. Februar 2024 /PRNewswire/ — Nach der erfolgreichen Einreichung des geistigen Eigentums (Intellectual Property, IP) für seine angewandte Plattformtechnologie, die auf das Endocannabinoid-System (ECS) abzielt,… Continue reading Tetra Pharm Technologies bringt den CB1-Antagonisten TPT0701 zur Appetitunterdrückung in die präklinische Testphase
Tetra Pharm Technologies procède à des essais précliniques sur l’antagoniste CB1, appelé TPT0701, destiné à la suppression de l’appétit
La société biopharmaceutique danoise Tetra Pharm Technologies est fière d’annoncer une étape importante dans le domaine de la recherche sur la suppression de l’appétit, grâce au développement d’un composé novateur s’appuyant sur sa plate-forme technologique innovante. COPENHAGUE, Danemark, 8 février 2024 /PRNewswire/ — Après avoir déposé avec succès une demande de propriété intellectuelle (PI) en… Continue reading Tetra Pharm Technologies procède à des essais précliniques sur l’antagoniste CB1, appelé TPT0701, destiné à la suppression de l’appétit
Tetra Pharm Technologies avanza el antagonista de CB1, TPT0701, para la supresión del apetito
-Tetra Pharm Technologies avanza el antagonista de CB1, TPT0701, para la supresión del apetito en pruebas preclínicas La empresa biofarmacéutica danesa Tetra Pharm Technologies se enorgullece de anunciar un hito importante en el ámbito de la investigación sobre la supresión del apetito al desarrollar un compuesto de vanguardia aprovechando su innovadora plataforma tecnológica. COPENHAGUE, Dinamarca,… Continue reading Tetra Pharm Technologies avanza el antagonista de CB1, TPT0701, para la supresión del apetito
Tetra Pharm Technologies advances CB1 antagonist, TPT0701, for appetite suppression into preclinical testing
The Danish biopharmaceutical company, Tetra Pharm Technologies, proudly announces a significant milestone in the realm of appetite suppression research having developed a cutting-edge compound leveraging their innovative platform technology. COPENHAGEN, Denmark, Feb. 8, 2024 /PRNewswire/ — Following the successful filing of Intellectual Property (IP) for their applied platform technology targeting the endocannabinoid system (ECS), Tetra… Continue reading Tetra Pharm Technologies advances CB1 antagonist, TPT0701, for appetite suppression into preclinical testing
Tetra Pharm Technologies advances CB1 antagonist, TPT0701, for appetite suppression into preclinical testing
The Danish biopharmaceutical company, Tetra Pharm Technologies, proudly announces a significant milestone in the realm of appetite suppression research having developed a cutting-edge compound leveraging their innovative platform technology. COPENHAGEN, Denmark, Feb. 8, 2024 /PRNewswire/ — Following the successful filing of Intellectual Property (IP) for their applied platform technology targeting the endocannabinoid system (ECS), Tetra… Continue reading Tetra Pharm Technologies advances CB1 antagonist, TPT0701, for appetite suppression into preclinical testing